Abstract：ObjectiveTo investigate the effect and adverse reaction of Telbivudine in the treatment of child-bearing period male patients with chronic hepatitis B.Methods68 cases of chronic hepatitis B from January to December in 2013 in our hospital were selected and divided into the treatment group(36 cases)and the control group(32 cases)according to different treatment methods.The treatment group was given Telbivudine therapy on the basis of liver protection and enzyme reduction,the control group was given only liver protection and enzyme reduction.The effect of the two groups was compared.ResultsThe level of HBV-DNA in the treatment group at 12,24 and 48 weeks was lower than that in the control group,with significant difference(P＜0.01).There was no significant difference in the ALT recover normal rate between the two groups at 4 and 8 weeks(P＞0.05).The recovery normal rate of ALT in the treatment group at 12 and 24 weeks was higher than that in the control group,with significant difference(P＜0.05).There was no significant difference in the HBsAg positive rate of the two groups at birth,6 months after birth and 12 months after birth (P＞0.05). There were 2 cases with elevated creatine kinase in the treatment group,all of which were elevated below grade 2,and there was 1 case of dizziness and nausea at first weeks of treatment.ConclusionTelbivudine has antiviral effect with relatively high efficiency,with less adverse reaction,it is safe for male of childbearing age.
宋慧萍. 替比夫定治疗育龄期男性慢性乙型肝炎患者的效果观察[J]. 中国当代医药, 2017, 24(14): 118-121.
Song Hui ping. Effect observation of Telbivudine in the treatment of child-bearing period male patients with chronic hepatitis B. 中国当代医药, 2017, 24(14): 118-121.
Sun J，Xie Q，Tan D，et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients：a randomized，controlled study[J].J Hepatology，2014，59（4）：1283-1292.
Liaw YF，Gane E，Leung N，et al.2-year GLOBE trial results：telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology，2009，136（2）：486-495.
[14]
Zou XJ，Jiang XQ，Tian DY.Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine[J].J Viral Hepatitis，2011，18（12）：892-896.
[15]
Goncalves J，laeufle R，Avila C.Increased risk with combination of telbivudine and pegylated-interferon alfa-2a in study CLDT600A2406 compared to uncommon rate with telbivudine monotherapy from the novartis global database [J].J Hepatol，2009，50（9）：S329-S330.
京公网安备 11010502046607号